METHODS	Treatment-naive patients with chronic hepatitis C genotype 2/3 infection were randomized to receive peginterferon alfa-2b ( 1.5 g/kg/wk ) for 24weeks ( group A ) ; peginterferon alfa-2b ( 1.0 g/kg/wk ) for 24weeks ( group B ) ; or peginterferon alfa-2b ( 1.5 g/kg/wk ) for 16weeks ( group C ) , each in combination with weight-based ribavirin ( 800-1200mg / d ) .\